NeuroXT has received FDA 510(k) clearance for NEXT-Cue, a Class II software device that combines brain MRI, demographic data and cognitive test results to estimate the likelihood that mild cognitive impairment will progress to Alzheimer's dementia within five years. The clearance moves imaging-derived prognostic markers from research settings into routine clinical decision-making. For longevity practice, it shortens the interval between the first detectable cognitive signal and the point at which intervention can be targeted.
Key Points
- FDA clears AI software estimating five-year progression risk from mild cognitive impairment
- Combines MRI imaging, demographics and cognitive testing into prognostic output
- Korean regulatory submission underway, commercialization planned for early next year
Longevity Analysis
Cognitive decline announces itself years before diagnosis, but the early signals are easily attributed to ageing, stress or poor sleep and therefore acted on late. Quantifying structural change in the brain against cognitive performance gives clinicians a defensible timeline rather than a vague concern, which is what makes sustained intervention — vascular risk control, metabolic correction, sleep architecture, reduction of neurotoxic exposures — worth committing to before symptoms consolidate. Prognostic precision matters less for what it predicts than for the window of disciplined action it opens.
Original published by LT Wire.